There are 3,893 papers on APOE in aging research: 137 trials and 2,856 observational studies in people, 489 in animals, 18 in cells, 275 reviews. The newest story, Nov 18, 2026: “Mice modeling late-onset Alzheimer’s show memory problems”.
APOE is linked with poorer cognition and higher dementia risk in humans, associations reported again by independent labs; independent labs also report senescence induction in human cells. Some cognitive results point the other way. Funders include the National Institute on Aging; some authors work at companies, and some papers declare company ties.
1,581 findings in 1,146 papers from 1993 to 2026, 161 of them since April 2026
Independent labs found the same change in cells, mice and people. 304 independent labs in 53 countries.
“The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001)”
Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
304 independent labs in 53 countries
127 findings against
Funders: National Institute on Aging and others
207 of 1,473 findings with company ties
Human trial137
Humans2,856
Animals484
Model organisms5
Cells18
In silico84
Interventions
2
Recombinant human APOE2
↓downin mouse cells1
1 study
Recombinant human APOE2 decreases APOE in ApoE4-knockin mouse primary neurons.
APOE is linked with worse cognitive function in humans (compared with noncarriers) (estimate -0.005, SE 0.001, P = .001).
“APOE ε4 carriage was associated with a significantly steeper quadratic age-associated decline in MMSE scores compared with noncarriers (estimate, -0.005; SE, 0.001; P = .001).”
Humanscompared with noncarriersmean 6.3 yearsn = 4,392
APOE is linked with worse cognitive function in humans (multiple TBIs) (-17.22 points compared with -7.21, P < .001).
“female APOE ε4 allele carriers with multiple TBIs exhibited worse outcomes on global cognition (P < .001; eg, ε4+/TBI2+ estimated marginal means [EMMs] from baseline to year 10 = -17.22 points”
The journals of gerontology. Series A, Biological sciences and medical sciences·
APOE was not clearly linked with cognitive function in humans (cognitively healthy or MCI, excluding dementia and ε4 homozygotes) (β = -0.36, p = .430).
“APOE status was not a significant predictor for performance on memory ( β = ‐0.36, p = .430) or attention ( β = 0.52, p = .265) measures.”
Humanscognitively healthy or MCI, excluding dementia and ε4 homozygotesn = 190
APOE was not clearly linked with cognitive function in humans (subjective cognitive decline) (p = 0.217).
“Findings from the linear mixed model indicated that ε4+ was not a significant predictor of cognitive decline in SCD patients over one year, p = 0.217.”
APOE is linked with higher inflammation in humans (independent of AD diagnosis).
“We identify a conserved, allele dose-dependent pro-inflammatory immune protein signature across peripheral and central tissues independent of AD diagnosis.”
Attention, executive function, mental flexibility, processing speed, verbal memory, and working memory response to aerobic exercise
↔no changein humans1
1 study
APOE showed no clear effect on attention, executive function, mental flexibility, processing speed, verbal memory, and working memory response to aerobic exercise in humans (APOE4 carriage moderation analysis in postmenopausal women with breast cancer).
“There were no other significant findings for attention, executive function, mental flexibility, processing speed, verbal memory, or working memory.”
Human trialAPOE4 carriage moderation analysis in postmenopausal women with breast cancer6 monthsfemalesn = 116
APOE impairs global cognition in humans (mild cognitive impairment, multidomain intervention) (mean difference = -2.08, 95% CI: -4.18 to 0.11, d = -0.56).
“APOE4‐positive participants showed attenuated global cognitive improvements from multidomain interventions compared to APOE4‐negative participants (mean difference = ‐2.08, 95% CI: ‐4.18 to 0.11; p = 0.052; d = ‐0.56).”
Human trialmild cognitive impairment, multidomain intervention6 monthsn = 67
Microglia increases APOE with aging, injury and AD-related pathology.
“microglia, oligodendrocyte-lineage cells, vascular-associated populations, and border-interface macrophages exhibit context-dependent induction that is strongly influenced by aging, injury, and AD-related pathology”
Reviewwith aging, injury and AD-related pathologycentral nervous system
Age-related hearing loss increases APOE in mice (age-related hearing loss).
“Validation via qRT-PCR, Western blot, and immunofluorescence demonstrated that both ApoE and Spp1 were highly expressed in the cochlea and auditory cortex of the ARHL mice”
APOE is linked with a higher risk of Alzheimer's disease in humans (p<10−6).
“Both approaches identified genome-wide significant associations (p<10−6) within the APOE locus, consistent with established Alzheimer’s disease risk factors.”
APOE is associated with Alzheimer's disease in humans (APOE-ε4 allele dosage) (11.1 vs 15.9 vs 23.7 per 1,000 person-years).
“the incidence rates (95% CI) of AD/ADRD per 1,000 person-years were 11.1 (8.8–13.9) in individuals without APOE-ε4, 15.9 (11.7–21.7) in those with one copy, and 23.7 (8.9–63.0) in those with two copies of APOE-ε4.”
APOE is associated with dementia in humans (Total sample and people without HIV; rs429358 and rs769449) (rs429358: P = 8.8×10 –18; rs769449: P = 1.48 × 10 –12).
“Across total sample and people without HIV, three genome-wide significant single nucleotide polymorphisms (SNPs) were identified: rs429358 (gene: APOE , P = 8.8×10 –18 )”
HumansTotal sample and people without HIV; rs429358 and rs769449
APOE is linked with a higher risk of dementia in humans (poor profile with APOE ε4 carriers vs favorable-profile non-carriers) (HR 2.32, 95% CI 1.73-3.12).
“Relative to favorable-profile APOE ε4 non-carriers, dementia risk was highest among participants with a poor profile who were APOE ε4 carriers (HR 2.32, 95% CI 1.73-3.12).”
Humanspoor profile with APOE ε4 carriers vs favorable-profile non-carriers31-year58% femalesn = 14,333
medRxiv : the preprint server for health sciences·Preprint
APOE is associated with dementia in humans (exploratory analyses).
“In exploratory analyses, apolipoprotein E ε4 genotype, thoracic aortic calcium, and plasma neurofilament light chain were associated with incident dementia”
Humansexploratory analysesmedian of 4.7 yearsn = 730
APOE is associated with cognitive function in humans (nonmetastatic breast cancer, exposed to endocrine therapy, at 5 years).
“At 5 years, however, women with breast cancer exposed to endocrine therapy and APOE4 carriers in particular exhibited lower learning and memory scores than other groups (P < .05).”
Humansnonmetastatic breast cancer, exposed to endocrine therapy, at 5 years5-year follow-upfemales
APOE is associated with cognitive function in humans (APOE ε4 carriage; adjusted for age, sex, and education).
“APOE ε4, diabetes, hypertension, and tobacco dependence each independently predicted lower performance across all four cognitive domains (adjusted p < .001)”
HumansAPOE ε4 carriage; adjusted for age, sex, and education62.0% femalesn = 3,833
APOE is associated with mortality in admixed Brazilian post-mortem cohort (BAS).
“we observed an excess of the ε4 European haplotypes in the BAS, which is consistent with a mortality pressure allelic effect in the European LA context.”
Alzheimer's & dementia : the journal of the Alzheimer's Association·
APOE is linked with a higher risk of mortality in humans (heterozygotes, compared with non-carriers) (HR 1.16 (95% CI 1.07-1.26)).
“APOE4 carriers (3264 [23%] of the cohort carried at least one ε4 allele) had a higher risk of all-cause mortality compared with non-carriers, with hazard ratios (HR) of 1·16 (95% CI 1·07-1·26) for heterozygotes”
Humansheterozygotes, compared with non-carriersmedian 15.4 yearsn = 14,091
APOE is associated with fractional anisotropy in humans (healthy individuals across the lifespan).
“We found significant associations between ApoE4 and FA in WM regions associated with neurodegenerative disease even in healthy individuals across the lifespan”
Humanshealthy individuals across the lifespanwhite matter
APOE is associated with fractional anisotropy in humans.
“There was a main effect of APOE, with APOE ɛ4 carriers having higher fractional anisotropy (FA) and lower axial diffusivity (AxD), mean diffusivity (MD), and radial diffusivity (RD) than non-carriers.”
APOE is associated with fractional anisotropy in humans.
“During ageing, common variants in genes that have been related to increased risk for neuropsychiatric disorders (APOE, HTT, MAPT) were associated in some studies with accelerated local FA decreases over time.”
APOE is linked with a higher risk of cardiovascular disease in humans (baseline non-statin users) (HR 1.18, 95% CI 1.02-1.38, p = .03).
“Among non-statin users, APOE4+ had higher incidence of total CVD (hazard ratio [95% confidence interval] = 1.18 [1.02-1.38], p = .03) compared with APOE3 carriers”
APOE is associated with executive function in humans (interaction with diet quality (HEI-2020); association present in noncarriers only) (p's = .056-.038).
“Interaction effects of HEI-2020*APOE-ε4 for EF and WM (p's = .056-.038) were such that diet quality”
Humansinteraction with diet quality (HEI-2020); association present in noncarriers onlyfemalesn = 102
Alzheimer's & dementia : the journal of the Alzheimer's Association·
APOE is associated with amyloid-beta deposition in humans (cognitively unimpaired at varying genetic risk for AD) (F(2, 42)=3.26, P=0.048; Ch4, F(2, 42)=3.82, P= 0.03).
“BFCS amyloid burden was highest among APOE ε4 homozygotes (Ch1-3, F(2, 42)=3.26, P=0.048; Ch4, F(2, 42)=3.82, P= 0.03).”
Humanscognitively unimpaired at varying genetic risk for ADbrain
APOE is associated with hippocampal volume in humans (baseline) (β = −0.27, p = 0.001).
“The APOE4 allele was significantly associated with lower hippocampus volume (Table, β = −0.27, p = 0.001) and higher PiB composite score (β = 0.48, p = 0.001).”
medRxiv : the preprint server for health sciences·Preprint
Learning and memory response to aerobic exercise
↓downin humans1
1 study
APOE is associated with learning and memory response to aerobic exercise in humans (Postmenopausal women with breast cancer; group × APOE4 carrier interaction) (Interaction b = -0.544, p = 0.023).
“APOE4 carriage moderated the effect of aerobic exercise on learning and memory (b = -0.544, p = 0.023).”
Human trialPostmenopausal women with breast cancer; group × APOE4 carrier interaction6 monthsfemalesn = 116
APOE is linked with dementia risk and poorer cognition in human studies from independent labs, although other human results show no clear cognitive difference. APOE ε4 is associated with hippocampal atrophy, while independent mouse studies report increased synaptic transmission. Papers and grants name the National Institute on Aging as a funder for 572 findings.
Human studies associate APOE with lifespan and higher Alzheimer’s disease risk, with cognitive-function associations reproduced by independent labs. Other studies report no effect on Alzheimer’s disease or cognition; independent labs also reproduce increased synaptic transmission and decreased cholesterol in mice. Papers and grants name the National Institute on Aging as a funder on 326 findings.
Summary rewritten as its findings changed.
As it read before
Independent labs link APOE to increased Alzheimer’s disease risk in humans, while other reports find no effect or lower risk. Human studies also associate APOE with longevity. The National Institute on Aging is a named funder; one registered trial ended over a year ago without posted results or a citing paper.
Summary rewritten as its findings changed.
As it read before
Independent labs report that APOE increases Alzheimer’s disease risk and impairs cognition in humans, and induces senescence in human cells. Human results also include unchanged or reduced Alzheimer’s disease risk and improved cognition; one registered trial ended over a year ago without posted results.
Summary rewritten as its findings changed.
As it read before
Independent labs reproduce APOE associations with Alzheimer's disease and dementia in human studies. Mortality associations point both ways: lower risk with ε2 versus ε3, but higher risk with two ε4 copies in epilepsy. Both registered trials are sponsored by Lexeo Therapeutics; one ended over a year ago without posted results, and papers declare maker interests.
At 12 months, genetically modified mice of both sexes remembered locations less well than unmodified controls and had modestly fewer projections per length of nerve-cell…At 12 months, genetically modified mice of both sexes remembered locations less well than unmodified controls and had modestly fewer projections per length of nerve-cell branch.
At age 75, estimated five-year risk of mild cognitive impairment was 17% with higher blood marker levels versus 7% with lower levels.At age 75, estimated five-year risk of mild cognitive impairment was 17% with higher blood marker levels versus 7% with lower levels.
Above-average exposure was linked to dementia and heart attack, with hazard ratios of 1.48 and 1.79, respectively, compared with lower exposure.Above-average exposure was linked to dementia and heart attack, with hazard ratios of 1.48 and 1.79, respectively, compared with lower exposure.
In experiments with 24 young male mice over 12 weeks, an antibody against asprosin reduced signs of chemically induced blood vessel aging.In experiments with 24 young male mice over 12 weeks, an antibody against asprosin reduced signs of chemically induced blood vessel aging.
Among 1,158 older adults at risk of dementia, 11 blood proteins were linked to differences in cognitive response to a lifestyle intervention.Among 1,158 older adults at risk of dementia, 11 blood proteins were linked to differences in cognitive response to a lifestyle intervention.